Skippet (formally MyMedBot) makes it possible for anyone to create software perfectly customised to their needs just by describing their problems in plain, everyday language. “Our mission is to put humans first in our digital world,” says Jacob Arnould. “We use artificial intelligence to enable computers to understand human language in order to configure apps through our no-code platform.”
Successful fundraising from the US and Europe
The first springboard for Skippet was the grant that the company received when it participated in Fit 4 Start in 2018. “Together with a small pre-seed round, it enabled us to scale MyMedBot, an online platform that helps schools and businesses create health and vaccine screening protocols,” Mr Arnould points out. “The platform has over 100,000 users today. Our customers are based primarily in the US, although we also have clients in the Middle East and Canada. Our international team is headquartered in Luxembourg.”
Our lead investor, US-based venture capital fund Neo, has vast experience in investing in no-code and artificial intelligence start-ups.
Skippet is the continuation of MyMedBot. “We leveraged our success to raise a $2.4 million seed round from Silicon Valley and European investors to take our company to the next level. Our lead investor, US-based venture capital fund Neo, has vast experience in investing in no-code and artificial intelligence start-ups and we are really happy to have them on board. Our next step is now to complete the beta version of Skippet with our customers. We can’t wait to see the look on people’s faces when they discover how much they can accomplish with Skippet!”